Video

Dr. Agarwal on Updated Results of the JAVELIN Renal 101 Trial in Advanced RCC

Author(s):

Neeraj Agarwal, MD

In Partnership With:

Neeraj Agarwal, MD, professor of medicine, physician and investigator, director, Genitourinary Oncology Program, Center of Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, discusses the updated results of the JAVELIN Renal 101 trial in advanced renal cell carcinoma (RCC).

Neeraj Agarwal, MD, professor of medicine, physician and investigator, director, Genitourinary Oncology Program, Center of Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, discusses the updated results of the JAVELIN Renal 101 trial in advanced renal cell carcinoma (RCC).

Originally presented at the 2018 ESMO Congress, the JAVELIN Renal 101 trial randomized over 800 patients to receive the combination of axitinib (Inlyta) plus avelumab (Bavencio) versus sunitinib (Sutent). Updated results from the trial showed a 5-month difference in progression-free survival (PFS) between arms among the overall population. In the control arm, the PFS was approximately 8 months compared with 13 months in the experimental arm. Response rates were superior in the combination arm by approximately 25%; however, the complete remission rate was 3%.

As these results are comparable to those of the phase III KEYNOTE-426 trial, it leaves physicians wondering what the best way to use these agents is, says Agarwal. Two years ago, the standard approach was to start with sunitinib. Now, many options, such as cabozantinib (Cabometyx) monotherapy, pembrolizumab (Keytruda) plus axitinib, axitinib plus avelumab, and ipilimumab (Yervoy) plus nivolumab (Opdivo), are available. Combinations of lenvatinib (Lenvima) plus pembrolizumab and cabozantinib-based combinations are also expected in the future, says Agarwal.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
Chelsey Schlechter, MPH, PhD
November 27th 2024

Dr Schlechter Named Cancer Moonshot Scholar

Carrie L. Kitko, MD, associate professor, pediatrics, medical director, the Pediatric Stem Cell Transplantation Program, the Ingram Professor of Pediatric Oncology, Monroe Carell Jr. Children’s Hospital at Vanderbilt; Sagar S. Patel, MD, director, Communications and Media Relationships, the Division of Hematology, the University of Utah Huntsman Cancer Institute
February 19th 2024

Kitko and Patel Emphasize the Importance of GVHD Research and Awareness

Douglas W. Sborov, MD, MS
October 28th 2024

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Regular Toxicity Monitoring

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

RCC: stock.adobe.com
October 1st 2024

Fecal Microbiota Transplantation Boosts Response to Pembrolizumab Plus Axitinib in mRCC

Renal Cell Carcinoma | Image Credit: © Crystal light - stock.adobe.com
September 17th 2024

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC